{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:17:33Z","timestamp":1778815053701,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T00:00:00Z","timestamp":1518566400000},"content-version":"vor","delay-in-days":289,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq","award":["APQ 402457\/2012-9"],"award-info":[{"award-number":["APQ 402457\/2012-9"]}]},{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa de Minas Gerais (FAPEMIG","award":["APQ-01797-12"],"award-info":[{"award-number":["APQ-01797-12"]}]},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa de Minas Gerais (FAPEMIG","award":["APQ-01070-13"],"award-info":[{"award-number":["APQ-01070-13"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.antiviral.2017.02.001","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:16:40Z","timestamp":1486081000000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Strategies for serum chemokine\/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases"],"prefix":"10.1016","volume":"141","author":[{"given":"Erica Godinho","family":"Menezes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordana Grazziela Alves","family":"Coelho-dos-Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila Melo","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gata","family":"Lopes-Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Jonathan-Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco T\u00falio","family":"Porto Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo Dias","family":"Cambraia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Bassetti","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-7361","authenticated-orcid":false,"given":"Luciana Diniz","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Peruhype-Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caren","family":"Chancey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-8348","authenticated-orcid":false,"given":"Ros\u00e2ngela","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.antiviral.2017.02.001_bib1","doi-asserted-by":"crossref","first-page":"e35106","DOI":"10.5812\/hepatmon.35106","article-title":"Relative importance of hepatitis B and C Viruses in hepatocellular carcinoma in EMRO countries and the Middle East: a systematic review","volume":"16","author":"Alavian","year":"2016","journal-title":"Hepat. Mon."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2017.02.001_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2013.07.010","article-title":"Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-\u03b12A and ribavirin therapy in patients with chronic hepatitis C","volume":"154","author":"Ara\u00fajo","year":"2013","journal-title":"Immunol. Lett."},{"issue":"2","key":"10.1016\/j.antiviral.2017.02.001_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000446398","article-title":"A\u00a013-year retrospective study on primary liver cancer in Cambodia: a strikingly high hepatitis C occurrence among hepatocellular carcinoma cases","volume":"91","author":"Chassagne","year":"2016","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.antiviral.2017.02.001_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0923-2516(96)80571-1","article-title":"Host and viral features in chronic HCV infection: relevance to interferon responsiveness","volume":"146","author":"Crax\u00ec","year":"1995","journal-title":"Res. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2017.02.001_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/CVI.00636-12","article-title":"Targeting the \u201ccytokine storm\u201d for therapeutic benefit","volume":"20","author":"D'Elia","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.antiviral.2017.02.001_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12866-015-0610-6","article-title":"Liver and blood cytokine microenvironment in HCV patients is associated to liver fibrosis score: a proinflammatory cytokine ensemble orchestrated by TNF and tuned by IL-10","volume":"16","author":"de Souza-Cruz","year":"2016","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.antiviral.2017.02.001_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1590\/S1678-9946201658037","article-title":"Impact of the pegylated-interferon and ribavirin therapy on the treatment-related mortality of patients with cirrhosis due to hepatitis C virus","volume":"58","author":"Dresch","year":"2016","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.antiviral.2017.02.001_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2014.04.010","article-title":"An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses","volume":"107","author":"Guo","year":"2014","journal-title":"Antivir. Res."},{"issue":"19","key":"10.1016\/j.antiviral.2017.02.001_bib9","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.3748\/wjg.v22.i19.4615","article-title":"Current treatment of chronic hepatitis C in China: dilemma and potential problems","volume":"22","author":"Han","year":"2016","journal-title":"World J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.antiviral.2017.02.001_bib10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/liv.13128","article-title":"All-oral daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: a sub-analysis in Asian patients from the Hallmark Dual study","volume":"36","author":"Kao","year":"2016","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.antiviral.2017.02.001_bib11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/003335491613100309","article-title":"Barriers to treatment among New York City residents with chronic hepatitis C virus Infection, 2014","volume":"131","author":"King","year":"2016","journal-title":"Public Health Rep."},{"key":"10.1016\/j.antiviral.2017.02.001_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.2009.05138.x","article-title":"Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation","volume":"1183","author":"Kong","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.antiviral.2017.02.001_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jir439","article-title":"Cytokine signatures of innate and adaptive immunity in 17DD yellow fever vaccinated children and its association with the level of neutralizing antibody","volume":"204","author":"Luiza-Silva","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2017.02.001_bib15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jhep.2013.04.007","article-title":"Treatment optimization of and prediction of HCV clearance in patients with acute HCV infection","volume":"59","author":"Mangia","year":"2013","journal-title":"J.\u00a0Hepatol."},{"issue":"11","key":"10.1016\/j.antiviral.2017.02.001_bib16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.medcli.2016.04.003","article-title":"Hepatitis C during pregnancy, vertical transmission and new treatment possibilities","volume":"147","author":"Mu\u00f1oz-G\u00e1mez","year":"2016","journal-title":"Med. Clin. Barc."},{"key":"10.1016\/j.antiviral.2017.02.001_bib17","article-title":"Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis","author":"Ogawa","year":"2016","journal-title":"Hepatol. Res."},{"issue":"2","key":"10.1016\/j.antiviral.2017.02.001_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/15284336.2015.1135553","article-title":"Addition of boceprevir to PEG-interferon\/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study","volume":"17","author":"Poizot-Martin","year":"2016","journal-title":"HIV Clin. Trials"},{"issue":"12","key":"10.1016\/j.antiviral.2017.02.001_bib19","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/ctr.12634","article-title":"Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant","volume":"29","author":"Punzalan","year":"2015","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.antiviral.2017.02.001_bib20","doi-asserted-by":"crossref","first-page":"27268","DOI":"10.1038\/srep27268","article-title":"A\u00a0Schisandra-derived compound schizandronic acid inhibits entry of pan-HCV genotypes into human hepatocytes","volume":"6","author":"Qian","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2017.02.001_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0153895","article-title":"Pretreatment predictors of response to PegIFN-RBV therapy in Egyptian patients with HCV genotype 4","volume":"11","author":"Rizk","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2017.02.001_bib22","first-page":"190","article-title":"Development and Validation of a simple, rapid and inexpensive PCR-RFLP method for genotyping of common IL28B polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response","volume":"12","author":"Sharafi","year":"2012","journal-title":"Hepat. Mon."},{"issue":"1","key":"10.1016\/j.antiviral.2017.02.001_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/0253-7184.176214","article-title":"Time trends of seroepidemiology of hepatitis C virus and hepatitis B virus coinfection in human immunodeficiency virus-infected patients in a Super Specialty Hospital in New Delhi, India: 2012-2014","volume":"37","author":"Sharma","year":"2016","journal-title":"Indian J. Sex. Transm. Dis."},{"key":"10.1016\/j.antiviral.2017.02.001_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13027-016-0076-7","article-title":"Systemic manifestations of hepatitis C infection","volume":"11","author":"Tang","year":"2016","journal-title":"Infect. Agent Cancer"},{"issue":"1","key":"10.1016\/j.antiviral.2017.02.001_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/875647939000600106","article-title":"Interpretation of the correlation coefficient: a basic review","volume":"6","author":"Taylor","year":"1990","journal-title":"J.\u00a0Diagnostic Med. Sonogr."},{"key":"10.1016\/j.antiviral.2017.02.001_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1742-4690-9-72","article-title":"Can immunotherapy be useful as a \"functional cure\" for infection with Human Immunodeficiency Virus-1?","volume":"9","author":"Vanham","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2017.02.001_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s40064-016-2190-9","article-title":"Simeprevir with peginterferon\/ribavirin for patients with hepatitis C virus genotype 1: high frequency of viral relapse in elderly patients","volume":"5","author":"Watanabe","year":"2016","journal-title":"Springerplus"},{"issue":"8","key":"10.1016\/j.antiviral.2017.02.001_bib28","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdw219","article-title":"The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma","volume":"27","author":"Wirth","year":"2016","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.antiviral.2017.02.001_bib29","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1128\/JVI.00587-15","article-title":"Identification of cholesterol 25-hydroxylase as a novel host restriction factor and a part of the primary innate immune responses against hepatitis C virus infection","volume":"89","author":"Xiang","year":"2015","journal-title":"J.\u00a0Virol."},{"issue":"8","key":"10.1016\/j.antiviral.2017.02.001_bib30","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/infdis\/jiq165","article-title":"Association of serum cytokine levels with treatment response to pegylated interferon and ribavirin therapy in genotype 1 chronic hepatitis C patients","volume":"203","author":"Yoneda","year":"2011","journal-title":"J.\u00a0Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2017.02.001_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000318896","article-title":"IL-8 is associated with non-viremic state and IFN-\u03b3 with biochemical activity in HCV-seropositive blood donors","volume":"54","author":"Zarife","year":"2011","journal-title":"Intervirology"},{"issue":"8","key":"10.1016\/j.antiviral.2017.02.001_bib32","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14656566.2016.1176143","article-title":"Ombitasvir\/paritaprevir\/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection","volume":"17","author":"\u0141ucejko","year":"2016","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630609X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630609X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T05:36:14Z","timestamp":1566452174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421630609X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":31,"alternative-id":["S016635421630609X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.001","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for serum chemokine\/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2017.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}